← Leaderboards
Jonathan S Wall
University Of Tennessee Knoxville
$10,502,422
Attributed
$10,627,298
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $945.1K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$10,627,298 · 6
By mechanism
R01$9,992,546 · 4
R21$385,000 · 1
R43$249,752 · 1
Top collaborators
- Suganya Selvarajah1 shared
Others in their field
Top investigators on “Amyloidosis”
- Eric Martin McDade · Washington University$98,616,192
- David Heimbrook · Leidos Biomedical Research, Inc.$56,561,099
- Randall J Bateman · Washington University$36,953,256
- Jeffery W Kelly · Scripps Research Institute$27,835,242
- Clifford Jack · University Of California Berkeley$17,085,178
- David Eisenberg · University Of California Los Angeles$13,649,212
Research focus
AmyloidosisProteinsDepositionIn VitroAmyloidCardiacOrganTissuesPeptidesPathologyIn VivoBaseAnimalsDiagnosisKidneyClinical TrialsReagentBiodistributionEvaluationLabelAmyloid ImagingAmyloid FibrilsImageClinic
Grant awards (22)
Development of a Theranostic Immunotherapy for Systemic Amyloidosis$425,568
R01 · FY2024 · DK · contact PI
Development of a Theranostic Immunotherapy for Systemic Amyloidosis$448,172
R01 · FY2023 · DK · contact PI
Development of a Theranostic Immunotherapy for Systemic Amyloidosis$443,300
R01 · FY2022 · DK · contact PI
Development of a Theranostic Immunotherapy for Systemic Amyloidosis$459,656
R01 · FY2021 · DK · contact PI
Development of chimeric antigen receptor-expressing macrophages for enhanced phagocytosis of systemic amyloid$175,000
R21 · FY2021 · AG · contact PI
Immunotherapeutic for ATTR/AL Cardiac Amyloidosis$249,752
R43 · FY2020 · HL
Development of chimeric antigen receptor-expressing macrophages for enhanced phagocytosis of systemic amyloid$210,000
R21 · FY2020 · AG · contact PI
Pre-targeting immunotherapy for light chain (AL) amyloidosis$350,000
R01 · FY2019 · DK · contact PI
Pre-targeting immunotherapy for light chain (AL) amyloidosis$350,000
R01 · FY2018 · DK · contact PI
Pre-targeting immunotherapy for light chain (AL) amyloidosis$350,000
R01 · FY2017 · DK · contact PI
Preclinical Diagnostic Imaging of Amyloid$395,202
R01 · FY2016 · DK · contact PI
Preclinical Diagnostic Imaging of Amyloid$395,202
R01 · FY2015 · DK · contact PI
Preclinical Diagnostic Imaging of Amyloid$395,202
R01 · FY2014 · DK · contact PI
Preclinical Diagnostic Imaging of Amyloid$395,202
R01 · FY2013 · DK · contact PI
Preclinical Diagnostic Imaging of Amyloid$435,627
R01 · FY2012 · DK · contact PI
Preclinical Diagnostic Imaging of Amyloid$420,101
R01 · FY2011 · DK · contact PI
Preclinical Diagnostic Imaging of Amyloid$451,374
R01 · FY2010 · DK · contact PI
Preclinical Diagnostic Imaging of Amyloid$464,016
R01 · FY2009 · DK · contact PI
SPECT/CT Imaging of Systemic AA-Amyloidosis in Mice$945,071
R01 · FY2005 · EB
SPECT/CT Imaging of Systemic AA-Amyloidosis in Mice$953,759
R01 · FY2004 · EB
SPECT/CT Imaging of Systemic AA-Amyloidosis in Mice$907,845
R01 · FY2003 · EB
SPECT/CT Imaging of Systemic AA-Amyloidosis in Mice$1,007,249
R01 · FY2002 · EB